Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBT (2016 - 2025)

Vanda Pharmaceuticals' EBT history spans 16 years, with the latest figure at -$38.0 million for Q4 2025.

  • On a quarterly basis, EBT fell 484.92% to -$38.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$138.6 million, a 504.89% decrease, with the full-year FY2025 number at -$138.6 million, down 504.89% from a year prior.
  • EBT hit -$38.0 million in Q4 2025 for Vanda Pharmaceuticals, down from -$28.4 million in the prior quarter.
  • Over the last five years, EBT for VNDA hit a ceiling of $12.6 million in Q2 2021 and a floor of -$38.0 million in Q4 2025.
  • Historically, EBT has averaged -$5.1 million across 5 years, with a median of -$890500.0 in 2023.
  • Biggest five-year swings in EBT: skyrocketed 740.29% in 2021 and later tumbled 5103.33% in 2024.
  • Tracing VNDA's EBT over 5 years: stood at $8.6 million in 2021, then grew by 11.65% to $9.6 million in 2022, then tumbled by 117.28% to -$1.7 million in 2023, then tumbled by 291.15% to -$6.5 million in 2024, then crashed by 484.92% to -$38.0 million in 2025.
  • Business Quant data shows EBT for VNDA at -$38.0 million in Q4 2025, -$28.4 million in Q3 2025, and -$34.9 million in Q2 2025.